Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia

American Heart Journal

Volumn 153, Issue 2, 2007, Pages 335.e1-335.e8

  Farnier, Michel ^a   Roth, Eli ^b   Gil Extremera, Blas ^c   Mendez, Gustavo F ^d   Macdonell, Geraldine ^e   Hamlin, Constance ^e   Perevozskaya, Inna ^e   Davies, Michael J ^e   Kush, Debra ^e   Mitchel, Yale B ^e  

^a Point Medical   (France)

^b Sterling Research Group   (United States)

^c HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^d Hospital de Especialidades No 14   (Mexico)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; EZETIMIBE PLUS SIMVASTATIN; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

ABDOMINAL PAIN; ADULT; AGED; ALLERGY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; MIXED HYPERLIPIDEMIA; MONOTHERAPY; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; MYALGIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 33846199963     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.10.031     Document Type: Article

References (20)

1. Durrington P. Dyslipidaemia. Lancet 362 (2003) 717-731
2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
3. Grundy S.M., Vega G.L., Yuan Z., et al. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (The SAFARI Trial). Am J Cardiol 95 (2005) 462-468
4. Farnier M., Freeman M., Macdonell G., et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur Heart J 26 (2005) 897-905
5. McKenney J.M., Farnier M., Lo K.W., et al. Safety and efficacy of long-term coadministration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 47 (2006) 1584-1587
6. Davidson M.H., McGarry T., Bettis R., et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 40 (2002) 2125-2134
7. Bays H.E., Ose L., Fraser N., et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin Ther 26 (2004) 1758-1773
8. Goldberg A.C., Sapre A., Liu J., et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 79 (2004) 620-629
9. Product Information. TRICOR (fenofibrate tablets) (2003), Abbott Laboratories, North Chicago (IL)
10. Vakkilainen J., Steiner G., Ansquer J.C., et al. Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes. Diabetes Care 25 (2002) 627-628
11. Vakkilainen J., Steiner G., Ansquer J.C., et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107 (2003) 1733-1737
12. Gardner C.D., Fortmann S.P., and Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 276 (1996) 875-881
13. Austin M.A., Breslow J.L., Hennekens C.H., et al. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
14. Packard C., Caslake M., and Shepherd J. The role of small, dense low density lipoprotein (LDL): a new look. Int J Cardiol 74 Suppl 1 (2000) S17-S22
15. Prueksaritanont T., Tang C., Qiu Y., et al. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 30 (2002) 1280-1287
16. Prueksaritanont T., Zhao J.J., Ma B., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 301 (2002) 1042-1051
17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
18. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
19. Keech A., Simes R.J., Barter P., et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 366 (2005) 1849-1861
20. ACCORD. http://www.accordtrial.org/public/index.cfm [accessed Sept 27, 2006].